---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-126276"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:09:12.395751+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics reports Q3 2024 net loss $12.7M, positive Phase 2 epetraborole PRO data in TR-MAC

## Summary
- Net loss $12.7M in Q3 2024 vs $16.7M in Q3 2023; cash $93.4M, expected to fund operations through 2027.
- Phase 2 portion of EBO-301: epetraborole achieved nominally significant improvements in QOL-B (p=0.0365) and MACrO2 (p=0.0433) vs placebo.
- Company plans to meet FDA in H1 2025 to discuss reinitiating Phase 3 TR-MAC study and top-line Phase 3 data in mid-2025.
- Achieved 50% reduction in expenditures through strategic realignment; R&D expenses decreased to $8.3M from $14.4M.
- Advancing boron chemistry pipeline: Chagas Phase 1 mid-2025, melioidosis Phase 2 enrollment H2 2025, and Gates Foundation grant.

## SEC filing metadata
- accession: 0000950170-24-126276
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000095017024126276/0000950170-24-126276-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000095017024126276/antx-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-126276
- JSON: https://secwatch.observer/filing/0000950170-24-126276.json
- Plain text: https://secwatch.observer/filing/0000950170-24-126276.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.